sj-docx-1-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-docx-1-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-3-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-3-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-7-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-7-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-6-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-6-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-2-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-2-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-5-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-5-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

sj-jpg-4-tan-10.1177_17562864241228350 – Supplemental material for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study

Supplemental material, sj-jpg-4-tan-10.1177_17562864241228350 for The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson’s disease psychosis: a 16-week, single-arm, open-label study by Virgilio G. H. Evidente, Daryl DeKarske, Bruce Coate and Victor Abler in Therapeutic Advances in Neurological Disorders</p

Neuropathological findings of PSP in the elderly without clinical PSP: Possible incidental PSP?

Aims: We aimed to describe cases with incidental neuropathological findings of progressive supranuclear palsy (PSP) from the Banner Sun Health Research Institute Brain and Body Donation Program. Methods: We performed a retrospective review of 277 subjects with longitudinal motor and neuropsychological assessments who came to autopsy. The mean Gallyas-positive PSP features grading for subjects with possible incidental neuropathological PSP was compared to those of subjects with clinically manifest disease. Results: There were 5 cases with histopathological findings suggestive of PSP, but no parkinsonism, dementia or movement disorder during life. Cognitive evaluation revealed 4 of the 5 cases to be cognitively normal; one case had amnestic mild cognitive impairment (MCI) in her last year of life. The mean age at death of the 5 cases was 88.9 years (range 80-94). All 5 individuals had histopathologic microscopic findings suggestive of PSP. Mean Gallyas-positive PSP features grading was significantly lower in subjects with possible incidental neuropathological PSP than subjects with clinical PSP, particularly in the subthalamic nucleus. Conclusions: We present 5 patients with histopathological findings suggestive of PSP, without clinical PSP, dementia or parkinsonism during life. These incidental neuropathological PSP findings may represent the early or pre-symptomatic stage of PSP. The mean Gallyas-positive PSP features grading was significantly lower in possible incidental PSP than in clinical PSP, thus suggesting that a threshold of pathological burden needs to be reached within the typically affected areas in PSP before clinical signs and symptoms appear. © 2011 Elsevier Ltd

Incidental Lewy body disease: Electrophysiological findings suggesting pre-clinical Lewy body disorders

Objective: Evaluate electrophysiologic findings in incidental Lewy body disease (ILBD). Methods: ILBD, Control, and Parkinson\u27s disease (PD) subjects had electrophysiological evaluation within 2. years prior to autopsy. Data analyzed included surface electromyography (EMG) of upper extremity muscles during rest and muscle activation, and electroencephalography (EEG) recording at rest. For EMG, gross tracings and spectral peaks were analyzed. EEG measures analyzed were background frequency and power in delta, theta, alpha, and beta bands. Results: Three of ten ILBD subjects (30%) showed unilateral rhythmic EMG discharges at rest without a visually apparent rest tremor. The ILBD resting EMG frequency was lower than in the Control group with no overlap (P=.03) and close to that of the PD group. The ILBD group had significantly lower background rhythm frequency than the Control group (P=.001) but was greater than the PD group (P=.01). Conclusions: The electrophysiologic changes in ILBD cases are between those of Control and PD, suggesting that these findings may reflect changes correlating with ILBD as a possible precursor to PD. Significance: Electrophysiologic changes in ILBD may assist with the identification of a preclinical stage for Lewy body disorders and help the development of a therapeutic agent for modifying Lewy body disease progression. © 2011 International Federation of Clinical Neurophysiology